How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation.
Elizabeth S AllenRandin C NelsonWilly Albert FlegelPublished in: Transfusion (2018)
Multiple hematopoietic progenitor cell (HPC) transplantation options for patients with sickle cell disease (SCD) are currently under investigation. Patients with SCD have a high rate of alloimmunization to red blood cell antigens, often complicating transfusion support. Transfusion reactions, including acute and delayed hemolytic reactions, have been observed despite immunosuppressive regimens. Allogeneic donor transplants have been shown to carry a risk of prolonged reticulocytopenia and acute hemolysis with severe anemia in nonmyeloablative regimens. We discuss our experience providing transfusion support to patients with SCD undergoing HPC transplantation, propose an outline for a complete pretransplantation evaluation, and discuss donor/recipient compatibility issues and their implications.
Keyphrases
- sickle cell disease
- red blood cell
- liver failure
- bone marrow
- end stage renal disease
- chronic kidney disease
- drug induced
- respiratory failure
- cardiac surgery
- ejection fraction
- cell therapy
- newly diagnosed
- stem cell transplantation
- peritoneal dialysis
- aortic dissection
- prognostic factors
- dendritic cells
- hepatitis b virus
- patient reported outcomes
- mesenchymal stem cells
- mechanical ventilation